Latest Breaking News On - Hutchinson china meditech - Page 1 : comparemela.com

A new drug application seeking the approval of fruquintinib for use in the treatment of patients with refractory metastatic colorectal cancer has been submitted to the FDA.

United statesHutchinson china meditechNorth americaAsia pacificChina meditechPatients with refractory metastatic colorectal cancerFresco 2 trialFruquintinib plus best supportive careDr michael shi